To print: Select File and then Print from your browser's menu

Title: Gabapentin May Play Role In Treating Chemotherapy-Induced Nausea

URL:

Lancet 2003;361:1703-05.
05/15/2003 07:00:00 PM
By Harvey McConnell

Gabapentin, an anticonvulsant, may play a role in the treatment of chemotherapy-induced nausea among breast cancer patients, according to the results of an open-label study. The results should be regarded as preliminary, say Dr Thomas Guttuso and colleagues at the Department of Neurology, University of Rochester, New York, because the study was without a placebo control as well as being open label. Delayed onset of nausea induced by chemotherapy remains a problem for about half of patients receiving moderately emetogenic chemotherapy, despite preventive treatment with a serotonin antagonist and dexamethasone, the clinicians point out. Working on the basis of an anecdotal report, they investigated gabapentin for acute (within 24 hour ) and delayed onset (2 to 5 days later) nausea. Dr Guttuso and colleagues surveyed the first 21 consecutive patients referred by oncologists at a cancer centre over 1 year. The first 9 who met the eligibility criteria of nausea severity 4 or greater after the first chemotherapy treatment, were enrolled. The patients were scheduled for 4 rounds, separated by 3 weeks, of adjuvant therapy with doxorubicin 60 mg/m[² and cyclophosphamide 600 mg/m². Nausea was measured by use of a diary, which the patient completed over 5 days. Gabapentin capsules (300 mg) were provided for the second and fourth rounds of treatment. Dosing began 5 days before chemotherapy with 1 capsule for 2 days, then twice daily for 2 days, followed by thrice daily for 6 days, and was discontinued on the sixth day after chemotherapy. All patients received intravenous ondansetron 16-24 mg, and intravenous dexamethasone 20 mg with or without intravenous lorazepam 0.5-1.0 mg before all chemotherapy treatments. Dr Guttuso and colleagues found that gabapentin therapy was associated with median reductions in both peak acute, and in delayed chemotherapy-induced nausea. Three patients, all of whom had a peak nausea rating of at least 6 points when not taking gabapentin, had complete cessation of both acute and delayed nausea. Three other patients had at least a 3- point improvement in peak delayed nausea. Eight of the 9 patients reported a reduction in peak delayed nausea score after taking the drug.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.